INTRODUCTION
Valvular heart disease is considered the next cardiovascular epidemic in developed countries, with a prevalence that rises exponentially with the ageing demographic. 1 Severe aortic stenosis (AS) is the most common form of valvular disease that requires intervention, 2 traditionally with surgical aortic valve replacement (SAVR). Transcatheter aortic valve implantation (TAVI) has rapidly evolved to become the treatment of choice for patients with severe AS, who are either inoperable or at high surgical risk. 3 Landmark multicentre randomised controlled trials of TAVI [4] [5] [6] [7] [8] [9] [10] have shown comparable or superior outcomes compared with SAVR, which has led to the widespread dissemination of this technology. 11 Ongoing trials are evaluating the efficacy of TAVI compared with SAVR in low-risk and intermediaterisk AS patient populations. 12 As the indications for TAVI expand to lower risk cohorts 12 with a corresponding shift in referral patterns from SAVR to TAVI,
KEY QUESTIONS
What is already known about this subject?
▸ Transcatheter aortic valve implantation (TAVI) is cost-effective compared with surgical aortic valve replacement (SAVR) for severe aortic stenosis; however, it is on average a more expensive procedure.
What does this study add?
▸ We have identified potentially modifiable factors that drive in-hospital costs for TAVI and SAVR. These include prolonged intensive care unit stay and the use of non-femoral access, for example.
How might this impact on clinical practice?
▸ We have identified potential areas for quality improvement efforts to reduce overall costs, and to improve the efficiency of care delivery for patients with severe aortic stenosis.
it is important to understand the relative resource intensity of each procedure. There have been multiple costeffectiveness analyses that have compared TAVI to SAVR in high-risk cohorts; the majority of these suggest that TAVI is an economic attractive intervention that represents good value. [13] [14] [15] [16] Investigators have evaluated the impact of complications on the hospitalisation costs associated with TAVI, and have found that complications contribute up to 25% of episode costs. [17] [18] [19] [20] However, there is a paucity of data on other patient-level and procedural-level drivers of healthcare cost associated with the episode of care for each of these procedures and specifically comparing the drivers for SAVR versus TAVI. Such data are important in order to identify potential modifiable factors, such that the efficiency of healthcare delivery can be improved. In the current economic climate of highly constrained healthcare budgets, it is imperative that the allocation of scarce healthcare resources be optimised.
Accordingly, the objective of our study was to address this gap in knowledge by evaluating healthcare costs associated with the episode of care for patients with severe AS undergoing either SAVR or TAVI in Ontario, Canada, and identifying the drivers of resource usage.
METHODS
This retrospective cohort study was conducted in the province of Ontario in Canada. Ontario has a population of ∼13.6 million, all of whom received publicly funded universal medical coverage, provided by a single third party payer, the Ontario Ministry of Health and Long Term Care (MOHLTC).
Data sources
All patients who underwent a SAVR or TAVI procedure from 1 April 2012 to 31 March 2013 were identified through the Cardiac Registry at the Cardiac Care Network (CCN) of Ontario. CCN includes a network of the 19 hospitals that offer invasive cardiac procedures including coronary artery bypass grafting (CABG), TAVI and SAVR. 21 22 CCN maintains a registry of all patients who have undergone these procedures, and contains data on patient demographics, comorbidities as well as procedural details including coronary anatomy. Data entry into the CCN Cardiac Registry is a mandatory prerequisite for provincial funding. The validity of the CCN Cardiac Registry has been evaluated through selected chart audits and core laboratory verification. 23 CCN is a prescribed entity under provincial privacy legislation, which permits CCN to collect and use personal patient information without the need for patient consent.
The Ontario Case Costing Initiative (OCCI) is a single source for integrated financial and clinical information that is available via the MOHLTC. Comprehensive primary costing data collection is performed by the accounting/costing centres at hospitals and includes both direct (eg, variable and fixed labour and both general and service-recipient specific supplies) and indirect costs. These are then merged with clinical information, including most responsible diagnosis, case-mix groupers, procedural information and length of hospital stay. During the time period of interest, 7 of the 11 cardiac surgery hospitals (of which 10 performed TAVI and all 11 performed SAVR) in the province were contributing data to OCCI. The cases captured in OCCI represented >50% of TAVI and SAVR volumes in the province.
Patients
We included all patients who underwent TAVI, isolated SAVR and combination SAVR+CABG at the six OCCI participating hospitals from 1 April 2012 to 31 March 2013.
Healthcare costs
Our primary outcome was individual-level cumulative healthcare costs for the index hospitalisation, defined as the acute hospitalisation during which the valve procedure was performed. All costs were reported in 2013 Canadian dollars.
Statistical analysis
Healthcare costs have a number of statistical properties that preclude the use of traditional statistical tools, including a heavily right-skewed distribution. 24 We used hierarchical generalised linear models with a logarithmic link and γ distribution to account for these features of costing data. [24] [25] [26] The models were clustered by hospital. The logarithmic link function restricts predicted costs to positive values, and produces final model coefficients that are straightforward to interpret. 27 Specifically, the exponential of the coefficient provides a rate ratio (RR) interpreted as the percentage increase in the mean cost for each unit change in the predictor. SAS V.9.3 (SAS Institute, Cary, North Carolina, USA) was used for all analyses; p values of <0.05 were considered significant.
RESULTS

Cohort
The cohort consisted of 1310 patients, of whom 585 underwent SAVR, 518 had combination SAVR+CABG, while 207 had TAVI. As seen in table 1, the groups had marked differences in their baseline characteristics, with older and higher risk patients undergoing TAVI. The mean age of patients undergoing isolated SAVR was 67.5 years, with the majority under the age of 75 years. In contrast, the mean age of the patients undergoing TAVI was 81.7 years, and they had a substantially higher comorbidity burden, including prevalence of lung disease, peripheral vascular disease and renal dysfunction, consistent with these being high-risk or inoperable patients.
Procedures
Less than 10% of the patients undergoing TAVI were urgent, and instead the major were outpatients who had 
Drivers of costs
Several patient-level factors were associated with an increased cost for the index hospitalisation (table 2) . Age over 75 years was a significant predictor for increased costs for isolated SAVR and TAVI. For SAVR, renal dysfunction and in particular being on dialysis was an important driver of higher costs associated with a 35% increase in mean costs, as was active endocarditis (31% increase in costs). For TAVI, lung disease was the comorbidity with the greatest impact on costs with an RR of 1.26 (95% CI 1.12 to 1.40; p<0.001), while active heart failure was a strong driver for combination CABG +SAVR (RR 1.28; 95% CI 1.16 to 1.41; p<0.001). Procedural factors of importance included the waittime location and urgency (table 2) . For TAVI, a nontransfemoral access was associated with an almost 30% increase in total costs. Patients undergoing TAVI who were discharged within 2 days of their procedure had a substantially lower cost compared with those with longer admissions (RR 1.42; 95% CI 1.14 to 1.78; p=0.0023). For all procedures, a long intensive care stay of >3 days was a strong driver of increased costs.
DISCUSSION
In this multicentre cohort study, we found wide variation in the cumulative healthcare costs associated with the index hospitalisation between SAVR, SAVR+CABG and TAVI and identified a number of potentially modifiable procedural drivers of healthcare costs. These represent areas for further study to determine if quality improvement initiatives targeting these areas will improve the efficiency of care delivery and translate to lower overall costs.
Although we found that the median costs for SAVR were substantially less than those for TAVI, it is important to recognise that the patients undergoing each of the procedures were vastly different, as is consistent with the high-risk/inoperable indication for TAVI. Multiple cost-effectiveness analyses have evaluated TAVI and SAVR for either inoperable or high-risk patients.
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These have generally found that TAVI is cost-effective. That said, even in these populations, previous literature has generally found TAVI to have higher overall costs. 13 This issue, coupled with a limited funding envelope and restricted capacity, reinforces the need to understand the major cost drivers. The transcatheter heart valve (THV) prosthesis itself has a substantial acquisition cost that is 5-6 times that of a surgical prosthesis. The bulk of the previous work on TAVI 17 18 20 33 and SAVR 34 related costs has focused on the importance of complications and the incremental costs associated with them. Our study contributes a number of novel insights to this body of literature. First, we found that the procedures had substantially different drivers of overall cost. There were a number of important patient-related factors that drove SAVR cost, including age, renal disease, lung disease, diabetes, recent myocardial infarction and endocarditis. In contrast, for TAVI, only older age and lung disease were statistically significant patientlevel drivers. We hypothesise that the greater relative importance of patient factors for SAVR-related costs is because patients undergoing SAVR more likely represent the full spectrum of operative risk from low, intermediate and high risk. In contrast, those for TAVI are almost exclusively either at high or prohibitive risk. The fact that there is a greater spectrum of patients would translate to a potentially greater impact of patient selection on SAVR cost. Lung disease is increasingly recognised as a poor prognostic factor for patients undergoing TAVI- our finding that it is one of the few patient factors that influence TAVI-related costs is consistent with these previous findings. Second, we found that procedural factors were key cost drivers in SAVR and TAVI. This is particularly important as these are modifiable. Both in TAVI and SAVR, the majority of the costs associated with the index episode of care are not prosthesis related. This is especially relevant to TAVI, given the high cost of THV currently. Although the acquisition cost of the THV prosthesis will decrease as technology improves and more transcatheter systems enter the marketplace, this is likely to be a protracted process. In contrast, the non-prosthesis-associated costs, in particular the potentially modifiable procedural drivers, are ones that may be more readily addressed in the short term. Indeed, there are a number of ongoing initiatives that are already targeting some of these drivers. Specifically, in TAVI, there is an emphasis on a 'minimalist' approach that uses local anaesthesia/conscious sedation rather than general anaesthesia. 35 36 The goal is that a less invasive procedure, coupled with explicit clinical care pathways that aim to mobilise patients early, result in shorter ICU stays and earlier discharge, both of which were major drivers of lower costs. Our finding that nontransfemoral approaches were associated with higher resource use reinforces this point.
Our study must be interpreted in the context of several limitations that merit discussion. First, our healthcare cost estimates were from fiscal year 2012-2013. For TAVI, where there have been rapid technological and procedural refinements, these costs may not be representative of current costs. However, we would expect that many of the patient and procedural drivers highlighted are likely to continue to be important. Second, we focused solely on the costs associated with the index hospitalisation and these represent only a fraction of the overall healthcare costs associated with each of these procedures. Both SAVR and TAVI require an extensive preprocedural workup including evaluation by a multidisciplinary Heart Team and the need for multiple diagnostic modalities, including coronary angiography and CT imaging often. For TAVI, excluded costs would also include any preprocedural revascularisation by angioplasty, which would typically occur at a separate sitting. Finally, ours was an observational data set, and thus there was most likely residual confounding that we could not account for despite the use of advanced statistical techniques. As such, our findings should be considered hypothesis generating.
In conclusion, we identified a number of patient and procedural factors that impact on healthcare costs for the index hospitalisation; some of these are potentially modifiable and may represent areas for quality improvement to optimise healthcare delivery.
